Russell Barton
Directeur des opérations chez ACUMEN PHARMACEUTICALS, INC.
Fortune : 309 006 $ au 30/04/2024
Postes actifs de Russell Barton
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| ACUMEN PHARMACEUTICALS, INC. | Directeur des opérations | 01/04/2019 | - |
AgeneBio, Inc.
 AgeneBio, Inc. BiotechnologyHealth Technology AgeneBio, Inc. develops an innovative therapeutics for unserved patients afflicted with neurological and psychiatric diseases to preserve and restore brain function. It research focused on cognitive neuroscience and the neurobiology of the aging brain with most advanced clinical program targets amnestic mild cognitive impairment (aMCI), the symptomatic, pre-dementia stage of Alzheimer’s. The company was founded by Michela Gallagher in 2008 and is headquartered in Baltimore, MD. | Directeur Technique/Scientifique/R&D | 01/10/2019 | - |
| Pharma Sagacity Consulting LLC | President | 01/01/2018 | - |
Historique de carrière de Russell Barton
Anciens postes connus de Russell Barton
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| ELI LILLY AND COMPANY | Directeur des opérations | - | - |
Formation de Russell Barton
| Illinois State University | Undergraduate Degree |
| Purdue University | Graduate Degree |
Statistiques
Internationale
| Etats-Unis | 7 |
Opérationnelle
| Chief Operating Officer | 2 |
| Undergraduate Degree | 1 |
| Graduate Degree | 1 |
Sectorielle
| Health Technology | 4 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| ACUMEN PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
AgeneBio, Inc.
AgeneBio, Inc. BiotechnologyHealth Technology AgeneBio, Inc. develops an innovative therapeutics for unserved patients afflicted with neurological and psychiatric diseases to preserve and restore brain function. It research focused on cognitive neuroscience and the neurobiology of the aging brain with most advanced clinical program targets amnestic mild cognitive impairment (aMCI), the symptomatic, pre-dementia stage of Alzheimer’s. The company was founded by Michela Gallagher in 2008 and is headquartered in Baltimore, MD. | Health Technology |
| Pharma Sagacity Consulting LLC |
- Bourse
- Insiders
- Russell Barton
- Expérience
